A systematic analysis of signaling reactivation and drug resistance

Boris N Kholodenko1, Nora Rauch2, Walter Kolch3

  • 1Systems Biology Ireland, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland; Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.

Cell Reports
|May 26, 2021
PubMed

Insights

Drug resistance stems from reactivated signaling pathways. Complete reactivation requires dual pathways, not just feedback loops, informing new drug combination strategies.

Area of Science:

  • Systems Biology
  • Pharmacology
  • Molecular Biology

Background:

  • Drug resistance is a significant challenge in cancer therapy.
  • Reactivation of signaling pathways is a known mechanism of drug resistance.
  • Network topology's role in this reactivation is not fully understood.

Purpose of the Study:

  • To investigate how different biological network structures influence signaling pathway reactivation after drug treatment.
  • To elucidate the mechanisms underlying network-dependent drug resistance.
  • To identify strategies for optimizing drug combinations to overcome resistance.

Main Methods:

  • Analysis of signaling network topologies under simulated drug treatment.
  • Mathematical modeling of pathway dynamics.
  • Experimental validation of predicted resistance mechanisms and drug combinations.

Main Results:

  • Feedback loops alone are insufficient for complete signaling reactivation.
  • Complete reactivation requires at least two distinct pathways (activating and inhibitory) from an upstream protein to a downstream output.
  • Drug-induced target dimerization and alleviation of negative feedback can paradoxically enhance pathway activity.

Conclusions:

  • Network context is crucial for understanding and predicting drug resistance.
  • Dual-pathway reactivation is a key mechanism for complete signaling restoration.
  • Targeted drug combinations, considering network topology and dimerization, can effectively block resistance, as demonstrated with RAF inhibitors against mutant NRAS signaling.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.8K
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
10.1K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K